For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250915:nRSO3025Za&default-theme=true
RNS Number : 3025Z Crystal Amber Fund Limited 15 September 2025
REACH - a non-regulatory announcement
15 September 2025
Crystal Amber Fund Limited
("Crystal Amber Fund", the "Company" or the "Fund")
Morphic Medical Inc. appoints new Chief Financial Officer
The Board of Crystal Amber Fund is pleased to see the announcement by Morphic
Medical Inc. ("Morphic Medical"), the medical device company that has
pioneered minimally invasive treatments of obesity and cardiometabolic
disorders in which it owns 96.7% of the issued share capital, that it has
appointed Jane Wright as its Chief Financial Officer.
Jane is a qualified accountant with over 30 years of experience including
several senior financial and operational positions in international medical
device companies, navigating complex regulatory environments and driving
strategic growth and operational efficiency.
Prior to joining Morphic Medical, she served as Finance & Operations
Director at Apollo Endosurgery, a specialist in endoluminal surgery (ELS)
procedures which was acquired by Boston Scientific Corporation in 2022.
Jane's arrival follows the appointment of Mike Gutteridge as Chief Executive
Officer in July and marks the latest milestone for the Morphic Medical
business.
Following recent CE Mark certification and commercial registration by the UK's
MHRA, RESET® is cleared for sale across key European markets, including
Germany where rollout has already begun. In her new role, Wright will play a
key role in shaping the company's long-term financial strategy and supporting
its continued growth.
Research presented to the IFSO World Congress of obesity experts this month
has shown that RESET® delivers substantial and durable benefits, with
patients losing an average of 18.9% of their total body weight, while also
improving blood sugar control.
Christopher Waldron, Chairman of Crystal Amber, commented: "We are pleased to
see Morphic Medical strengthening its executive team as the momentum within
the business continues to build."
For further enquiries please contact:
Crystal Amber Fund Limited
Chris Waldron (Chairman)
Tel: 01481 742 742
www.crystalamber.com (http://www.crystalamber.com)
Allenby Capital Limited - Nominated Adviser
Jeremy Porter/ Dan Dearden-Williams
Tel: 020 3328 5656
Winterflood Investment Trusts - Broker
Joe Winkley/Neil Langford
Tel: 020 3100 0160
Crystal Amber Advisers (UK) LLP - Investment Adviser
Richard Bernstein
Tel: 020 7478 9080
About Reach announcements
This is a Reach announcement. Reach is an investor communication service
aimed at assisting listed and unlisted (including AIM quoted) companies
to distribute media only / non-regulatory news releases into the public
domain. Information required to be notified under the AIM Rules for Companies,
Market Abuse Regulation or other regulation would be disseminated as an RNS
regulatory announcement and not on Reach.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NRAVZLFFEKLFBBZ